[go: up one dir, main page]

WO2002003071A3 - Modulators of trk protein activity, compositions and uses - Google Patents

Modulators of trk protein activity, compositions and uses Download PDF

Info

Publication number
WO2002003071A3
WO2002003071A3 PCT/US2001/021472 US0121472W WO0203071A3 WO 2002003071 A3 WO2002003071 A3 WO 2002003071A3 US 0121472 W US0121472 W US 0121472W WO 0203071 A3 WO0203071 A3 WO 0203071A3
Authority
WO
WIPO (PCT)
Prior art keywords
trk
compositions
trk protein
modulators
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021472
Other languages
French (fr)
Other versions
WO2002003071A2 (en
Inventor
Alan Thomas Bates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pangene Corp
Original Assignee
Pangene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangene Corp filed Critical Pangene Corp
Priority to AU2001273245A priority Critical patent/AU2001273245A1/en
Publication of WO2002003071A2 publication Critical patent/WO2002003071A2/en
Anticipated expiration legal-status Critical
Publication of WO2002003071A3 publication Critical patent/WO2002003071A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention concerns receptor tyrosine kinases and ligands therefore that modulate cell growth, differentiation, and survival. Particularly, the present invention concerns the TrK family of receptor tyrosine kinases known to mediate the activities of neurotrophins. TrK proteins are also known proto-oncogenes. Small molecule compositions for the modulation of TrK protein binding and activity are provided. Also provided are methods for screening for small molecules capable of binding to TrK protein binding one or more neurotrophin binding determinants in TrK proteins.
PCT/US2001/021472 2000-07-05 2001-07-05 Modulators of trk protein activity, compositions and uses Ceased WO2002003071A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001273245A AU2001273245A1 (en) 2000-07-05 2001-07-05 Modulators of trk protein activity, compositions and uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21577800P 2000-07-05 2000-07-05
US60/215,778 2000-07-05

Publications (2)

Publication Number Publication Date
WO2002003071A2 WO2002003071A2 (en) 2002-01-10
WO2002003071A3 true WO2002003071A3 (en) 2003-01-30

Family

ID=22804345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021472 Ceased WO2002003071A2 (en) 2000-07-05 2001-07-05 Modulators of trk protein activity, compositions and uses

Country Status (2)

Country Link
AU (1) AU2001273245A1 (en)
WO (1) WO2002003071A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196061B2 (en) * 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
JP2008029296A (en) * 2006-07-31 2008-02-14 Hisamitsu Pharmaceut Co Inc Neuroblastic therapeutic agent, screening method thereof, and method of determining prognosis of neuroblastic
IL274740B2 (en) * 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals containing a human TRKB locus
JPWO2022009992A1 (en) * 2020-07-10 2022-01-13

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622862A (en) * 1991-04-23 1997-04-22 Regeneron Pharmaceuticals, Inc. Assay systems for trkB neurotrophin activity
WO1999033482A1 (en) * 1997-12-31 1999-07-08 University Of Utah Research Foundation Uses of alpha-conotoxin peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622862A (en) * 1991-04-23 1997-04-22 Regeneron Pharmaceuticals, Inc. Assay systems for trkB neurotrophin activity
WO1999033482A1 (en) * 1997-12-31 1999-07-08 University Of Utah Research Foundation Uses of alpha-conotoxin peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
URFER R ET AL: "AN IMMUNOGLOBULIN-LIKE DOMAIN DETERMINES THE SPECIFICITY OF NEUROTROPHIN RECEPTORS", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 12, 15 June 1995 (1995-06-15), pages 2795 - 2805, XP000568880, ISSN: 0261-4189 *
WINDISCH J M ET AL: "BRAIN-DERIVED NEUROTROPHIC FACTOR, NEUROTROPHIN-3, AND NEUROTROPHIN-4 BIND TO A SINGLE LEUCINE-RICH MOTIF OF TRKB", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 34, no. 35, 5 September 1995 (1995-09-05), pages 11256 - 11263, XP002062138, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
WO2002003071A2 (en) 2002-01-10
AU2001273245A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
WO1998024432A3 (en) Use of indolinone compounds as modulators of protein kinases
AU3801997A (en) Assays for protein kinases using fluorescent protein substrates
WO2008028168A3 (en) Serine-threonine protein kinase and parp modulators
WO2001083755A3 (en) Human anti-cd40 antibodies and methods of making and using same
MX9604316A (en) Protein tyrosine kinase agonist antibodies.
EP2409704A3 (en) c-Met modulators and methods of use
AU1756601A (en) Dye labeled imidazoquinoline compounds
WO2005020921A3 (en) C-kit modulators and methods of use
WO2005113596A3 (en) Cell surface receptor isoforms and methods of identifying and using the same
DE69738930D1 (en) METHODS FOR MODULATING MELANINE SYNTHESIS
AU2003209636A1 (en) Novel chemokine binding peptides capable of modulating the biological activity of chemokines
WO2000048621A3 (en) Methods and compositions for regulating protein-protein interactions
WO2005016966A3 (en) Intron fusion proteins, and methods of identifying and using same
WO2001023412A3 (en) Methods of screening for agents which inhibit aggregation of polypeptides
WO2002065134A3 (en) Modulators of p53-p300 interactions and screening methods therefor
WO2002003071A3 (en) Modulators of trk protein activity, compositions and uses
WO2002002751A3 (en) Alteration of cell membrane
WO2002005843A3 (en) Human rrp sequences and methods of use
WO2003020892A3 (en) Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
GB2322132B (en) Keratinocyte growth factor-2 products
WO2001009326A9 (en) Constitutively active stat proteins and their uses for identifying modulators of activity including dysproliferative cellular changes
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
CA2330025A1 (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src
WO2002053726A3 (en) Protein-protein interactions in adipocyte cells
WO2002026929A3 (en) Kini-3 motor protein and methods for its use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP